{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for alpha root_Display\ Name in (root_Display Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
21 CFR 338
(2017)
Source URL:
First approved in 1955
Source:
NDA202100
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
ANDA091135
(2012)
Source URL:
First approved in 1948
Source:
NDA018279
Source URL:
Class:
POLYMER
Status:
Investigational
Source:
NCT01145560: Phase 2 Interventional Completed Severe Sepsis
(2010)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT01483287: Early Phase 1 Interventional Completed Irritable Bowel Syndrome
(2011)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
